Nature Reviews Gastroenterology & Hepatology

Papers
(The H4-Index of Nature Reviews Gastroenterology & Hepatology is 67. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Zolbetuximab treatment in metastatic gastric cancer763
Hybrid EASL Congress 2023740
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology673
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis627
Mapping neuroimmune interactions in the gut614
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed556
2023 FDA approvals in gastroenterology and hepatology462
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa392
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection386
Advancing nutrition science for global health322
The future of treating pancreatic exocrine insufficiency317
Actin cytoskeletal dynamics in hepatic myofibroblasts and fibrosis309
Nomenclature of HBV core protein-targeting antivirals306
Western lifestyle, metaflammation and the cell of origin of colon cancer261
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection254
Black–White disparities across the colorectal cancer care continuum in the USA253
Large language models for clinical decision support in gastroenterology and hepatology236
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis235
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health229
Artificial intelligence and automation in endoscopy and surgery221
New understanding of hepatobiliary MRI212
Metastatic pancreatic cancer and the liver204
Food as medicine in gastrointestinal cancer therapy203
A crucial Fusobacterium nucleatum clade in colorectal cancer201
Inflammatory bowel disease in pregnancy and breastfeeding187
Lessons from incretin-based therapy in MASH and obesity186
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease179
The critical role of gut–brain signalling in eating behaviour and obesity178
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract176
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges170
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation162
Novel insights into chronic HBV infection162
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases157
Hepatocyte-derived biomarkers in alcohol-related cirrhosis156
Integrated systems approach to identify environmental factors in intestinal inflammation145
Characterizing the genomic landscape of colorectal cancer140
Implications of the evolving knowledge of the genetic architecture of MASLD139
Probiotics for preterms: sharing complex decision-making135
Estimating dietary intake from human stool DNA133
HDCA ameliorates NAFLD in mice126
Preventing the progression of cirrhosis to decompensation and death119
Medical therapy of paediatric inflammatory bowel disease118
SSRIs and depression: role of gut–brain communication117
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment116
The path to successful hepatitis C elimination in Spain107
Human intestinal B cells in inflammatory diseases103
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease102
Proteases in intestinal health and disease101
Metabolic diseases in the East Asian populations101
Liver, ageing and disease97
Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus97
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management94
Phase III results for first-line treatment for metastatic colorectal cancer93
ECCO’2488
Microbiota and colorectal cancer — controlling for confounders challenges associations87
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’85
Enteric nervous system transfers stress to the gut82
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance82
Author Correction: Hepatic immune regulation and sex disparities79
The future of pathology in gastroenterology and hepatology76
GLP1R agonists in NAFLD: a promising therapy on the horizon75
HIV-associated gut microbiome influences gut mucosal immunity73
Human deskilling in medical artificial intelligence: prohibited or permissible under the EU Artificial Intelligence Act?72
Hepatic inflammatory responses in liver fibrosis70
NAFLD prevalence in older patients with T2DM70
Hepatic glucose metabolism in the steatotic liver69
Transforming the landscape of liver cancer detection and care68
SMART cancer risk prediction67
Artificial intelligence in liver cancer — new tools for research and patient management67
Liver dialysis in ACLF67
0.2386589050293